on Menarini Industrie Farmaceutiche Riunite
Menarini Group Presents Promising Oncology Data at ASCO 2026
Menarini Group, in cooperation with its subsidiary Stemline Therapeutics, has announced new data at the 2026 ASCO Annual Meeting. This includes findings from seven presentations covering both solid tumors and hematologic diseases. Highlighting the regimen of elacestrant with capivasertib from the ELEVATE study, the data suggest potential advancements for metastatic breast cancer (mBC), along with monotherapy options in adjuvant breast cancer.
Additionally, findings on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm and a late-breaking presentation on selinexor in myelofibrosis will be revealed. Menarini emphasizes its mission of providing targeted therapies for under-treated cancers, with studies like ELEGANT, ADELA, and ELECTRA underscoring this commitment.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Menarini Industrie Farmaceutiche Riunite news